Bayer, Foundation Medicine Team Up on NGS-Based Companion Diagnostics
May 29 2019 - 8:45AM
Dow Jones News
By Pietro Lombardi
Bayer AG (BAYN.XE) said Wednesday that it is teaming up with
Foundation Medicine, Inc to develop and commercialize
genetic-sequencing technology for cancer.
The company didn't disclose financial details of the
agreement.
"This agreement allows for collaboration across multiple
oncology drug candidates and approved therapies developed by Bayer
and covers Foundation Medicine's full portfolio of tests," Bayer
said.
The technology, called NGS-based companion diagnostic, helps
gather information from a patient's tumor which can be used to
guide treatment decisions.
Write to Pietro Lombardi at pietro.lombardi@dowjones.com
(END) Dow Jones Newswires
May 29, 2019 08:30 ET (12:30 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Bayer Aktiengesellschaft (PK) (USOTC:BAYRY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bayer Aktiengesellschaft (PK) (USOTC:BAYRY)
Historical Stock Chart
From Apr 2023 to Apr 2024
